Effect of direct thrombin inhibition with Bivalirudin (Hirulog) on restenosis after coronary angioplasty

Am J Cardiol. 1998 Aug 15;82(4):511-5. doi: 10.1016/s0002-9149(98)00371-3.

Abstract

The direct antithrombin, bivalirudin, did not reduce angiographic restenosis measured either as the dichotomous restenosis rate of 62% for bivalirudin and 58% for heparin (p = 0.70), or as the late loss in lumen diameter of 0.44 +/- 0.47 mm for bivalirudin and 0.39 +/- 0.53 mm for heparin (p = 0.62). Direct thrombin inhibition with bivalirudin neither reduces angiographic restenosis nor alters the impact of several established risk factors for restenosis.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Angioplasty, Balloon, Coronary*
  • Antithrombins / therapeutic use*
  • Coronary Disease / diagnostic imaging
  • Coronary Disease / prevention & control*
  • Coronary Disease / therapy
  • Female
  • Heparin / therapeutic use
  • Hirudin Therapy
  • Hirudins / analogs & derivatives*
  • Humans
  • Linear Models
  • Male
  • Middle Aged
  • Peptide Fragments / therapeutic use*
  • Radiography
  • Recombinant Proteins / therapeutic use
  • Recurrence
  • Risk Factors
  • Treatment Outcome

Substances

  • Antithrombins
  • Hirudins
  • Peptide Fragments
  • Recombinant Proteins
  • Heparin
  • bivalirudin